Table 2. Clinical and instrumental results at the follow-up evaluation.
| Variable | Group Aa | Group Bb | Difference between the groups (p-value) | ||
|---|---|---|---|---|---|
| Mean penile curvature (°) | <0.001 | ||||
| Baseline | 40 (30–45) | 35 (27–40) | |||
| Follow-up | 32 (28–34) | 31 (28–33) | |||
| Difference between baseline and follow-up (p) | |||||
| Mean plaque size (mm) | <0.001 | ||||
| Baseline | 18±10 | 19±11 | 0.34 | ||
| Follow-up | 15±10 | 17±9 | |||
| Mean IIEF-5 (range) | <0.001 | ||||
| Baseline | 21 (19–23) | 20 (19–23) | <0.001 | ||
| Follow-up | 24 (21–27) | 22 (20–22) | |||
| Mean VAS (range) | <0.001 | ||||
| Baseline | 5 (3–5) | 5 (3–5) | >0.99 | ||
| Follow-up | 1 (0–1) | 1 (0–1) | |||
| PGI-I | 1±1 | 3±2 | <0.001 | ||
Values are presented as median (range) or mean±standard deviation. Total number of patients who completed the follow-up: 81.
IIEF-5: international index of erectile function, VAS: visual analogue scale, PGI-I: patient's global impressions of improvemen
aOral and intralesional administration hyaluronic acid. bIntralesional hyaluronic acid administration.